Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality

Kang, Ting; Huang, Yukun; Zhu, Qianqian; Cheng, Hao; Pei, Yuanyuan; Feng, Jingxian; Xu, Min-Jun; Jiang, Gan; Song, Qing; Jiang, Tianze; Chen, Hongzhuan; Gao, Xiaoling; Chen, Jun

doi:10.1016/j.biomaterials.2018.02.033

Cited by 88 publications

(60 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TDLNs‐targeted nanoparticles increased the amount of cytokines IL‐12p70 and IFN‐γ, which conduce to delaying the tumor growth and remarkably reducing lung metastasis. Similar results are reported for CpG‐loaded nanoparticles coupled with exogenous or endogenous antigens and necroptotic cancer‐cells‐mimicry nanovaccines, respectively …”

Section: Nanomaterials For Target Deliverysupporting

confidence: 85%

“…Besides these two signals, a variety of cytokines secreted by APCs and T cells, such as IL‐2, function as a common supplementary signal to completely activate T lymphocytes. Indeed, liposomes, carbon nanotubes, iron/dextran nanoparticles, red blood cells, PLGA nanoparticles, and other biomimetic platforms have been explored as aAPCs . For example, magnetic nanoclusters were functionalized with biomimetic leucocyte membranes .…”

Section: Developing Novel Nanoplatforms For Stimulating Cellular Immumentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Nanomaterials For Target Deliverysupporting

confidence: 85%

Section: Developing Novel Nanoplatforms For Stimulating Cellular Immumentioning

confidence: 99%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

show abstract

“…Preparation and characterization of the Nano-sapper. The inner cores of Nanosapper were prepared by water-in-oil microemulsions in an oil phase containing cyclohexane/Igepal® CO-520 solution (72/28, v/v), as described previously with modification 35,60,61 . In general, 300 μL of 5 M CaCl 2 and 30 μL of 8 mg/mL LMWP was mixed in 20 mL oil phase with continuous stirring to form the calcium part.…”

Section: Discussionmentioning

confidence: 99%

Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors

et al. 2020

Self Cite

View full text Add to dashboard Cite

The failure of immunotherapies in immune-excluded tumor (IET) is largely ascribed to the void of intratumoral cytotoxic T cells (CTLs). The major obstacles are the excessive stroma, defective vasculatures and the deficiency of signals recruiting CTLs. Here we report a dualmechanism based CTLs infiltration enhancer, Nano-sapper, which can simultaneously reduce the physical obstacles in tumor microenvironment and recruiting CTLs to potentiate immunotherapy in IET. Nano-sapper consists a core that co-loaded with antifibrotic phosphatesmodified α-mangostin and plasmid encoding immune-enhanced cytokine LIGHT. Through reversing the abnormal activated fibroblasts, decreasing collagen deposition, normalizing the intratumoral vasculatures, and in situ stimulating the lymphocyte-recruiting chemoattractants expression, Nano-sapper paves the road for the CTLs infiltration, induces the intratumoral tertiary lymphoid structures, thus reshapes tumor microenvironment and potentiates checkpoint inhibitor against IET. This study demonstrates that the combination of antifibrotic agent and immune-enhanced cytokine might represent a modality in promoting immunotherapy against IET.

show abstract

“…56 Therefore, the "articial necroptotic cancer cell", named aHSP70p-CM-CaP, was developed to deliver tumour membrane proteins plus additional boosting adjuvants. 57 Aer the administration of aHSP70p-CM-CaP, effective lymph node trafficking and strong T cells response were detected in mice. Especially, when combined with a PD-1 antibody, aHSP70p-CM-CaP vaccination could result in the killing of tumour cells and mediate tumour regression in B16OVA melanoma mice.…”

Section: Combination Treatment Of Pd-1/pd-l1 Inhibitors and Tumour Vamentioning

confidence: 94%

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade

2019

View full text Add to dashboard Cite

show abstract

Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality

Cited by 88 publications

References 42 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade

Contact Info

Product

Resources

About